Michael Barbella, Managing Editor10.06.23
DiFusion Technologies Inc. has announced results of a recent case series that notes the benefits of the company's proprietary ZFUZE technology.
The first U.S. Food and Drug Administration-cleared advanced biomaterial for spinal implants, ZFUZE is proven to create a highly favorable cellular and immunologic response post-surgery. Among a number of findings, the case series showed ZFUZE offers a
92.3% fusion rate at eight months and no device migration.
ZFUZE is a composite polymer derived from PEEK and negatively charged ceramic aluminum silicate molecules. ZFUZE is a hydrophilic load bearing medical polymer, that provides for bony ingrowth into the implant and affords the surgeon the ability to verify fusion radiographically.
A recent study conducted by a team at the McGowan Institute for Regenerative Medicine compared macrophage expression changes in-vitro with ZFUZE and PEEK. The team led by Stephen Badylak, M.D., Ph.D., (McGowan Institute deputy director) tested more than 300 biomaterials using these same M1 to M2 immunomodulation assays. ZFUZE is the first and only man-made material that consistently demonstrated the ability to shift the M1 to M2 phenotype in a rapid and predictable manner at day four to five.
Representatives for DiFusion Technologies will share more findings at the North American Spine Society's (NASS) 38th annual meeting and conference in Los Angeles later this month. "NASS is known on a global scale for its reputation as the most influential spine organization," DiFusion Technologies CEO Derrick Johns said. "We're excited to participate, but even more excited for the 600,000 patients who undergo a spinal fusion each year. With ZFUZE, many of those procedures will require less downtime and have fewer complications."
DiFusion Technologies develops advanced biomaterials for surgical implants. Its solutions reduce the foreign body response from the patient's immune system, thereby promoting early healing, reducing complications, and improving patient outcomes. The company's proprietary manufacturing process produces implants that decrease chronic inflammation currently associated with mainstream biomaterials.
The first U.S. Food and Drug Administration-cleared advanced biomaterial for spinal implants, ZFUZE is proven to create a highly favorable cellular and immunologic response post-surgery. Among a number of findings, the case series showed ZFUZE offers a
92.3% fusion rate at eight months and no device migration.
ZFUZE is a composite polymer derived from PEEK and negatively charged ceramic aluminum silicate molecules. ZFUZE is a hydrophilic load bearing medical polymer, that provides for bony ingrowth into the implant and affords the surgeon the ability to verify fusion radiographically.
A recent study conducted by a team at the McGowan Institute for Regenerative Medicine compared macrophage expression changes in-vitro with ZFUZE and PEEK. The team led by Stephen Badylak, M.D., Ph.D., (McGowan Institute deputy director) tested more than 300 biomaterials using these same M1 to M2 immunomodulation assays. ZFUZE is the first and only man-made material that consistently demonstrated the ability to shift the M1 to M2 phenotype in a rapid and predictable manner at day four to five.
Representatives for DiFusion Technologies will share more findings at the North American Spine Society's (NASS) 38th annual meeting and conference in Los Angeles later this month. "NASS is known on a global scale for its reputation as the most influential spine organization," DiFusion Technologies CEO Derrick Johns said. "We're excited to participate, but even more excited for the 600,000 patients who undergo a spinal fusion each year. With ZFUZE, many of those procedures will require less downtime and have fewer complications."
DiFusion Technologies develops advanced biomaterials for surgical implants. Its solutions reduce the foreign body response from the patient's immune system, thereby promoting early healing, reducing complications, and improving patient outcomes. The company's proprietary manufacturing process produces implants that decrease chronic inflammation currently associated with mainstream biomaterials.